Erythropoiesis-stimulating agentPhase 3 trialInvestigational
Luspatercept
How it works
Stimulates the production of red blood cells, reducing the need for blood transfusions in patients with anemia due to myelodysplastic syndromes or myeloproliferative neoplasms.
Cancer types
Leukemia— All patients
Efficacy
In clinical trials, around 50% of patients achieved a reduction in transfusion burden, with a median overall survival of approximately 1 year.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.